Vascular endothelial cell growth factors (VEGFs) are secreted polypeptides with a highly conserved cystine-knot structure similar to that of the platelet-derived growth factors (PDGFs).  VEGFs play important roles in vascular development and in diseases involving abnormal growth of blood vessels such as tumor-related angiogenesis. VEGFs stimulate angiogenesis by binding to the specific receptors (VEGFRs) on the surface of vascular endothelial cells. All the three VEGFRs, VEGFR1 (Flt-1), VEGFR2 (KDR/Flk-1/CD309), and VEGFR3 (Flt-4), belong to the CSF-1/PDGF receptor subfamily of receptor tyrosine kinase superfamily (RTKs). Each VEGFR contains 7 immunoglobulin (Ig)-like C2-type domains in the extracellular region and an intracellular kinase domain. VEGFR3 is widely expressed in the early embryo but restricted to lymphatic vessels at later stages of development. VEGFR3 is up-regulated in tumor angiogenesis. VEGFC and VEGFD have been identified as ligands for VEGFR3. VEGFR3 plays a significant role in ligand-mediated lymphangiogenesis. Mutation in this gene is associated with the primary lymphedema, a rare genetic condition with both autosomal dominant and autosomal recessive modes of inheritance. The VEGFR3-mediated signaling pathway may provide a target for anti-lymphangiogenic therapy in cancer.

Vascular endothelial cell growth factors (VEGFs) are secreted polypeptides with a highly conserved cystine-knot structure similar to that of the platelet-derived growth factors (PDGFs).  VEGFs play important roles in vascular development and in diseases involving abnormal growth of blood vessels such as tumor-related angiogenesis. VEGFs stimulate angiogenesis by binding to the specific receptors (VEGFRs) on the surface of vascular endothelial cells. All the three VEGFRs, VEGFR1 (Flt-1), VEGFR2 (KDR/Flk-1/CD309), and VEGFR3 (Flt-4), belong to the CSF-1/PDGF receptor subfamily of receptor tyrosine kinase superfamily (RTKs). Each VEGFR contains 7 immunoglobulin (Ig)-like C2-type domains in the extracellular region and an intracellular kinase domain. VEGFR3 is widely expressed in the early embryo but restricted to lymphatic vessels at later stages of development. VEGFR3 is up-regulated in tumor angiogenesis. VEGFC and VEGFD have been identified as ligands for VEGFR3. VEGFR3 plays a significant role in ligand-mediated lymphangiogenesis. Mutation in this gene is associated with the primary lymphedema, a rare genetic condition with both autosomal dominant and autosomal recessive modes of inheritance. The VEGFR3-mediated signaling pathway may provide a target for anti-lymphangiogenic therapy in cancer.

 

Product Details

 

Gene Symbol: FLT4; PCL; FLT-4; LMPH1A; VEGFR3

 

NCBI Gene ID: 2324

 

Uniprot Entry: P35916

 

Construct Details: The recombinant human FLT4-Fc fusion is expressed as a 525 amino acid protein consisting of Tyr25 - Thr323 region of FLT4 and a C-terminal Fc from human IgG1, which exists as a dimer under non-reducing conditions.

 

Source:  Human cells stably expressing FLT4-Fc and growing in chemical-defined media with no animal components or antibiotics.

 

Deduced Amino Acid Sequence:

        10         20         30         40         50         60 

YSMTPPTLNI TEESHVIDTG DSLSISCRGQ HPLEWAWPGA QEAPATGDKD SEDTGVVRDC  

        70         80         90        100        110        120 

EGTDARPYCK VLLLHEVHAN DTGSYVCYYK YIKARIEGTT AASSYVFVRD FEQPFINKPD 

       130        140        150        160        170        180 

TLLVNRKDAM WVPCLVSIPG LNVTLRSQSS VLWPDGQEVV WDDRRGMLVS TPLLHDALYL 

       190        200        210        220        230        240 

QCETTWGDQD FLSNPFLVHI TGNELYDIQL LPRKSLELLV GEKLVLNCTV WAEFNSGVTF 

       250        260        270        280        290        300 

DWDYPGKQAE RGKWVPERRS QQTHTELSSI LTIHNVSQHD LGSYVCKANN GIQRFRESTG 

       310        320        330        340        350        360 

THTCPPCPAP ELLGGPSVFL FPPKPKDTLM ISRTPEVTCV VVDVSHEDPE VKFNWYVDGV 

       370        380        390        400        410        420 

EVHNAKTKPR EEQYNSTYRV VSVLTVLHQD WLNGKEYKCK VSNKALPAPI EKTISKAKGQ  

       430        440        450        460        470        480 

PREPQVYTLP PSREEMTKNQ VSLTCLVKGF YPSDIAVEWE SNGQPENNYK TTPPVLDSDG 

       490        500        510        520 

SFFLYSKLTV DKSRWQQGNV FSCSVMHEAL HNHYTQKSLS LSPGK

 

M.W.: Calculated molecular mass (kDa): 59.1; Estimated by SDS-PAGE under reducing condition (kDa): 70-80

 

Calculated PI: 5.63

 

Calculated Extinction Coefficients(M-1 cm-1, at 280nm): 102175

 

Purity: >95% judged by SDS-PAGE under reducing condition (see the gel image above)

 

Formulation: Supplied at 0.5 mg/ml in sterile PBS pH7.4 (carrier free).

 

Endotoxin Level: <0.1 EU per 1 μg of purified recombinant protein determined by the LAL method

 

Biological Activity: Binds VEGF-C and VEGF-D  and inhibits VEGF-dependent proliferation of human umbilical vein endothelial cells (HUVECs)

 

  

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.

 

Storage

 

The product is shipped at 4°C. Upon receipt, centrifuge the product briefly before opening the vial. It is recommended to store small aliquots at the temperature below –20°C for long-term storage and the product is stable for 3 months. The undiluted protein can be stored at 4°C for no more than 2 weeks.

 

 

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

 

References

 

1. Cancer. Res. 52: 5738-5743 (1992).

2. Oncogene. 9: 3545-3555 (1994).

3. Proc. Natl. Acad. Sci. 95: 548-553 (1998).

4. FASEB. J. 15: 1028-1036 (2001).

5. Nature. 454: 656-660 (2008).

 

 

 

Documentation

 

Product datasheet (pdf) can be downloaded here: FCL00J3-PDS.pdf

 

 

 

Additional supporting documents, including COA and MSDS are available upon request.

 

 

 

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE IN HUMAN.

Restriction: This product is not transferable or re-sellable.  Customer obtain no right to transfer, assign, or sublicense its use rights, or to transfer, resell, package, or otherwise distribute the product, or to use the product for the benefit of any third party or for any commercial purpose.  Customer may only use the product in compliance with applicable local, state and federal laws, regulations and rules.  Customer may not directly or indirectly use the product or allow the transfer, transmission, export or re-export of all or any part of the product in violation of any export control law or regulation of the united states or any other relevant jurisdiction.  Your use of this product constitutes acceptance of the terms of this limited use agreement.  Please refer to our “terms & conditions” for details.  If you are not willing to accept the limitation of this agreement, G&P Biosciences will accept return of the product for a full/partial refund.